Compounds › Neuro and cognition

Selank (TP-7)

Russian peptide anxiolytic, Semax's counterpart

Partially approvedNeuro and cognition

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Summary

Peptide developed in Russia, studied for anxiety relief and mild focus support. Also called TP-7. It is registered in Russia. It is Semax's partner in the so-called Russian nootropic duo: Semax pulls toward activation, Selank toward restraint.

Quick reference

Route: Subcutaneous or nasal spray. One route per cycle.
Schedule: SC: 1×/day for 4 weeks, then 4 weeks off. Intranasal: 14–21 days on, 1–3 weeks off.
Measure: U-100 syringe for the SC route.
Status: Russian clinical use since the 1990s. Not approved by the FDA.

SubQ Schedule

Phase	Duration	Daily dose	Notes
Initiation	Weeks 1-2	250-300 mcg	1×/day. Baseline tolerance check.
Maintenance	Weeks 3-4	400-500 mcg	Step up only if the lower dose felt safe and stable.
Cycle off	Weeks 5-8	0 mcg	Four-week rest used in community protocols.
Repeat	Weeks 9-12	300-500 mcg	Resume at the dose that worked best.

Selank Nasal Spray Dosage and Intranasal Protocol

Phase	Duration	Daily dose	Notes
Standard course	14-21 days	600-2,700 mcg	Split into 2-3 daily sprays per Russian clinical practice.
Washout	1-3 weeks	0 mcg	Rest period before repeating the course.

Selank Dosage Chart

Route	Reference amount	Frequency	Duration	Evidence level
SubQ	250–500 mcg	1×/day in the community schedules summarized on this page	Common community schedule on this page: 4 weeks	Community-reported research practice; not a validated clinical dose
Intranasal	600–2,700 mcg per day	Divided across 2–3 daily doses	14-21 days	Published Russian clinical reference summarized on this page

Selank 10 mg Reconstitution Math

Vial size	BAC water added	Concentration	250 mcg	300 mcg	500 mcg
10 mg	1 mL	10,000 mcg/mL	0.025 mL (2.5 units)	0.03 mL (3 units)	0.05 mL (5 units)
10 mg	2 mL	5,000 mcg/mL	0.05 mL (5 units)	0.06 mL (6 units)	0.10 mL (10 units)

Selank 10 mg Reconstitution Math

Vial size	BAC water added	Concentration	250 mcg dose	300 mcg dose	500 mcg dose
30 mg	3 mL	10,000 mcg/mL	0.025 mL (2.5 units)	0.03 mL (3 units)	0.05 mL (5 units)
30 mg	6 mL	5,000 mcg/mL	0.05 mL (5 units)	0.06 mL (6 units)	0.10 mL (10 units)
30 mg	10 mL	3,000 mcg/mL	0.083 mL (8.3 units)	0.10 mL (10 units)	0.167 mL (16.7 units)

Selank Timeline & What to Monitor

Phase	What May Shift	What to Track
Days 1-3	Mild calm. Possible first-dose headache.	Sleep quality, headache, injection-site reaction.
Day 4-7	Anxiolytic effect more consistent.	Daily anxiety self-rating (0-10 scale), focus, mood.
Day 8-14	Stable response in most users in the published record.	Anxiety, sleep, energy, side effects.
End of cycle	Russian trials report effect carryover for about a week after stopping.	Note any rebound, sleep changes, or mood dip.

Selank vs Semax vs Diazepam

Feature	Selank	Semax	Diazepam
Class	Tuftsin analogue heptapeptide	ACTH(4-10) analogue heptapeptide	Benzodiazepine (small molecule)
Primary mechanism	GABA modulation, serotonin shifts, enkephalin stabilization	BDNF/NGF upregulation, dopamine and serotonin modulation	GABA-A positive allosteric modulator
Half-life	~2-10 min plasma; 12-24 hr functional duration	~3-5 min plasma; 20-24 hr functional duration	20-100 hours
Primary use	Anxiolytic / nootropic	Nootropic / neuroprotective	Anxiolytic / sedative / anticonvulsant
Daily dose	250-500 mcg SubQ	300-800 mcg SubQ	2-10 mg oral
FDA status	Not approved	Not approved	FDA-approved
Dependence risk	None reported in published Russian trials	None reported in published Russian trials	Significant (Schedule IV)
Cognitive effects	Mild nootropic (memory, attention)	Stronger nootropic (memory, learning, focus)	Impairs memory and cognition

Selank Cycle Length Evidence

Source	Active period	What happened next	What it supports
Current Russian medical-use instructions	14 days	May be repeated after 1-3 weeks when needed and after clinician consultation	Official duration and repeat timing for the Russian intranasal product
Medvedev et al., 2014	14 days	Patients were followed after treatment; the paper reported that the measured anxiolytic effect remained for at least 7 days after the last administration	A 14-day human Selank monotherapy course with post-course follow-up
Medvedev et al., 2015	14 days for the main treatment period	20 patients in the Selank group continued Selank for another 7 days, through day 21	A human study that included a 21-day Selank extension in a specific treatment design

Intranasal vs Injectable Selank Cycle Evidence

Route or context	Human cycle evidence	Cycle-length takeaway
Intranasal Russian product	Yes	14-day labeled course; repeat timing of 1-3 weeks is stated in the current instructions
Published human Selank studies	Yes	14-day courses are documented, with a 21-day extension in one 2015 study
Subcutaneous injection	No validated human cycle identified in the reviewed sources	Do not present a 4-week, 8-week, or other injectable cycle as clinically proven
Animal or laboratory studies	Preclinical only	Useful for mechanism research, but their durations should not be converted into a human cycle

Selank Cycle Length vs Selank Dosing Protocol

Question	Best page
How long is a Selank cycle?	This Selank cycle guide
How long is the break between courses?	This Selank cycle guide
Can a course be repeated?	This Selank cycle guide
What did 14-day and 21-day studies do?	This Selank cycle guide
What is the Selank dosage?	Selank protocol
How do you reconstitute a Selank vial?	Selank protocol
How many U-100 syringe units are used in a calculation?	Selank protocol
How do nasal and SubQ dose amounts compare?	Selank protocol

Storage and handling

The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.

Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
Cloudy solution, with particles or a color change: discard. There is no recovery.

Lab tests and monitoring

This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.

Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.

Evidence limits

What these numbers are and what they are not. The values above were preserved exactly as they appear in the source, without reinterpretation. What the source describes as community practice is marked as such in the tables; what came from a published trial is too. A dose repeated by many people does not become a validated dose by repetition.

Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.

← Back to all compounds